Krystal Biotech, Inc. (KRYS)
303.49
-2.19
(-0.72%)
USD |
NASDAQ |
Nov 13, 10:38
Krystal Biotech Enterprise Value : 8.154B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 8.154B |
| November 11, 2026 | 8.247B |
| November 10, 2026 | 8.179B |
| November 09, 2026 | 8.077B |
| November 06, 2026 | 8.012B |
| November 05, 2026 | 7.993B |
| November 04, 2026 | 8.307B |
| November 03, 2026 | 8.135B |
| November 02, 2026 | 7.865B |
| October 30, 2026 | 8.943B |
| October 29, 2026 | 8.713B |
| October 28, 2026 | 8.621B |
| October 27, 2026 | 8.596B |
| October 26, 2026 | 8.391B |
| October 23, 2026 | 8.327B |
| October 22, 2026 | 8.583B |
| October 21, 2026 | 8.643B |
| October 20, 2026 | 8.739B |
| October 19, 2026 | 8.586B |
| October 16, 2026 | 8.477B |
| October 15, 2026 | 8.875B |
| October 14, 2026 | 8.895B |
| October 13, 2026 | 8.613B |
| October 12, 2026 | 8.936B |
| October 09, 2026 | 8.923B |
| Date | Value |
|---|---|
| October 08, 2026 | 8.795B |
| October 07, 2026 | 8.714B |
| October 06, 2026 | 8.780B |
| October 05, 2026 | 9.019B |
| October 02, 2026 | 8.646B |
| October 01, 2026 | 8.736B |
| September 30, 2026 | 8.951B |
| September 29, 2026 | 9.080B |
| September 28, 2026 | 9.139B |
| September 25, 2026 | 9.398B |
| September 24, 2026 | 9.373B |
| September 23, 2026 | 9.278B |
| September 22, 2026 | 9.548B |
| September 21, 2026 | 9.044B |
| September 18, 2026 | 9.127B |
| September 17, 2026 | 9.189B |
| September 16, 2026 | 9.127B |
| September 15, 2026 | 9.128B |
| September 14, 2026 | 9.227B |
| September 11, 2026 | 9.433B |
| September 10, 2026 | 9.390B |
| September 09, 2026 | 9.465B |
| September 08, 2026 | 9.559B |
| September 04, 2026 | 9.766B |
| September 03, 2026 | 10.16B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Ionis Pharmaceuticals, Inc. | 4.834B |
| Ultragenyx Pharmaceutical, Inc. | 2.577B |
| BridgeBio Pharma, Inc. | 18.15B |
| Cytokinetics, Inc. | 7.958B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 63.07M |
| Revenue (Quarterly) | 127.34M |
| Total Expenses (Quarterly) | 64.27M |
| EPS Diluted (Quarterly) | 2.045 |
| Gross Profit Margin (Quarterly) | 92.91% |
| Profit Margin (Quarterly) | 49.53% |
| Earnings Yield | 2.43% |
| Operating Earnings Yield | 2.45% |
| Normalized Earnings Yield | 2.426 |